Pharma Company AmyriAD Steps into the Light with Phase III Symptom Relief Drug for Alzheimer’s Disease

After starting up in stealth mode, AmyriAD is ready to debut its Phase 3 investigational drug to relieve Alzheimer’s symptoms. AmyriAD will be attending the Clinical Trials of Alzheimer’s Disease Conference as a Silver Sponsor. November 10th, 2021 – AmyriAD – a biopharmaceutical company led by the development strategist who introduced the cognition enhancing medication…